Skip to main content

AZN · Astrazeneca PLC · Documents

Track AZN — free
$184.02 -0.43 (-0.23%) At close · Nov 16 Q1 2026 earnings call transcript
Market Cap
$285.40B
Shares
1.55B
Volume · Nov 16 1.95M Avg daily vol (3M) 3.03M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $58.74B up 8.6% 20-F filed Feb 24, 2026 Earnings call Q1 2026 earnings call Held Apr 29, 2026
2026
Nov 16
Current report 6-K
Baxfendy recommended for EU hypertension approval

AstraZeneca said Baxfendy (baxdrostat) was recommended for EU approval for adults with uncontrolled hypertension. If approved, it would be the EU’s first and only aldosterone synthase inhibitor; two Phase III trials showed reductions of 15.7 mmHg and 16.6 mmHg in systolic blood pressure.

3 source passages
AstraZeneca's Baxfendy (baxdrostat) has been recommended for approval in the European Union (EU) for the treatment of adults with arterial hypertension insufficiently controlled with at least two antihypertensive medicinal products. If approved, Baxfendy will be the first and only aldosterone synthase inhibitor (ASI) in the EU, directly targeting aldosterone to address a key biological driver of elevated blood pressure. Baxfendy 2mg lowered office systolic blood pressure by 15.7 mmHg from baseline in BaxHTN trial and 24-hour ambulatory systolic blood pressure by 16.6 mmHg from baseline in Bax24 trial Open the document at this passage
Nov 16
Current report 6-K
Imfinzi plus EV approved in US for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi plus EV (enfortumab vedotin) received US approval for perioperative treatment of adults with muscle-invasive bladder cancer ineligible for or refusing cisplatin-based chemotherapy. The VOLGA Phase III trial showed 49% lower recurrence risk and 42% lower death risk.

2 source passages
AstraZeneca’s Imfinzi (durvalumab) in combination with enfortumab vedotin (EV) as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based chemotherapy. Based on VOLGA Phase III trial data which showed a 49% reduction in risk of recurrence and a 42% reduction in risk of death, with a manageable safety profile Open the document at this passage
Nov 16
Current report 6-K
Klygefa gains EU approval for generalised myasthenia gravis

AstraZeneca PLC reported that Klygefa (gefurulimab) received European Union (EU) approval as an add-on to standard therapy for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis, based on positive PREVAIL Phase III trial results.

4 source passages
AstraZeneca PLC Klygefa (gefurulimab) approved in the EU for the treatment of adults with generalised myasthenia gravis (gMG) Alexion, AstraZeneca Rare Disease’s Klygefa (gefurulimab) has been approved in the European Union (EU) as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. Approval based on PREVAIL Phase III trial demonstrating statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living score Open the document at this passage
Nov 2
Current report 6-K
11,948 Further Securities Admitted to London Stock Exchange

AstraZeneca PLC admitted 11,948 further securities to the London Stock Exchange - Main Market, bringing total securities in issue to 1,551,065,237; they were issued between 1 October 2026 to 31 October 2026 under employee share schemes.

6 source passages
AstraZeneca PLC 11,948 London Stock Exchange - Main Market 1,551,065,237 Issued between 1 October 2026 to 31 October 2026 Admission of shares under the Company’s employee share schemes Open the document at this passage
Nov 2
Current report 6-K
Total voting rights: 1,551,065,237

AstraZeneca PLC reports 1,551,065,237 total voting rights as at 31 October 2026, with no shares held in Treasury.

Source passage
As at 31 October 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,065,237 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,551,065,237. Open the document at this passage
Oct 30
Current report 6-K
Current report

AstraZeneca reported 9M 2026 total revenue up 7% at constant exchange rates and Core EPS up 14%, supported by double-digit growth in Oncology, R&I and Rare Disease.

Read from the first part of this long document
Oct 27
Current report 6-K
Current report

AstraZeneca and Daiichi Sankyo’s Enhertu won EU approval on 27 October 2026 for residual HER2-positive early breast cancer; DESTINY-Breast05 showed a 53% reduction in recurrence or death, and a $75 million milestone is due to Daiichi Sankyo.

Oct 22
Current report 6-K
Current report

AstraZeneca PLC’s Ultomiris received accelerated approval in the US on 22 October 2026 as the first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A nephropathy, showing a 43.4% reduction versus placebo at 34 weeks.

Oct 5
Current report 6-K
Current report

AstraZeneca completed its $2 billion equity investment in Summit Therapeutics on 5 October 2026, accelerating development of ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF, and planning broader combination programmes.

Oct 2
Current report 6-K
Current report

AstraZeneca entered a clinical collaboration agreement with Daiichi Sankyo and Summit Therapeutics to evaluate Datroway with ivonescimab across multiple tumour types, beginning with a Phase III trial in 1st-line triple-negative breast cancer.

Oct 1
Current report 6-K
Current report

AstraZeneca PLC issued 9,828 fully fungible Ordinary Shares of $0.25 each between 1 September 2026 and 30 September 2026 under employee share schemes; admission to the London Stock Exchange - Main Market brought total securities in issue to 1,551,053,289.

Oct 1
Current report 6-K
Current report

AstraZeneca PLC reported 1,551,053,289 total voting rights as at 30 September 2026, based on 1,551,053,289 ordinary shares of US$0.25, with no shares held in Treasury.

Sep 29
Current report 6-K
Current report

AstraZeneca announced a $2 billion equity investment in Summit Therapeutics and a clinical collaboration to combine ivonescimab with sonesitatug vedotin in gastrointestinal cancers, with trials intended to begin imminently and broader ADC combinations planned.

Sep 23
Current report 6-K
Current report

AstraZeneca PLC announced European Commission approval of Trixeo as maintenance treatment for asthma in patients 12 years and older uncontrolled on medium-dose ICS/LABA, following positive KALOS and LOGOS Phase III trial results showing improved lung function and reduced severe exacerbations.

Sep 21
Current report 6-K
Current report

AstraZeneca’s Klygefa received a positive CHMP recommendation for EU approval as an add-on to standard therapy for adults with anti-acetylcholine receptor (AChR) antibody-positive generalised myasthenia gravis.

Sep 21
Current report 6-K
Current report

AstraZeneca’s Enhertu was recommended for EU approval for residual HER2-positive early breast cancer; DESTINY-Breast05 found a 53% reduction in invasive disease recurrence or death versus T-DM1.

Showing 1–50 of 789 documents
Key facts CIK 901832 CUSIP G0593M107 13F (30d) 1094 filings 1075 filers Visit website Investor relations